Event Details

The Immatics team will be at the 2026 ASCO® Annual Meeting in Chicago.

Details on Oral Presentations
 

PRAME Cell Therapies: Anzu-cel (IMA203) and IMA203CD8 (GEN2)
Title: Patient-level clinical response dynamics in advanced melanoma with anzutresgene autoleucel (anzu-cel), a PRAME-directed T-cell receptor (TCR) T-cell therapy
Presenting author: Davar Diwakar, MD
Session: Oral Abstract Session - Melanoma/Skin Cancers
Abstract ID: 9508
Abstract/Slides Link: Melanoma/Skin Cancers

Title: Phase 1a study results for IMA203CD8, a PRAME-directed T-cell receptor (TCR) T-cell therapy, in ovarian cancer
Presenting author: Antonia Busse, MD
Session: Rapid Oral Abstract Session – Gynecologic Cancer
Abstract ID: 5509
Abstract/Slides Link: Gynecologic Cancer

Title: Phase 1 study results with PRAME-directed T-cell receptor (TCR) T-cell therapies in synovial sarcoma
Presenting author: Dejka M. Araujo, MD
Session: Rapid Oral Abstract Session - Sarcoma
Abstract ID: 11516
Abstract Link: Sarcoma

MAGEA4/8 Bispecific: IMA401
Title: First-in-human results with IMA401, a MAGEA4/8 targeted T-cell receptor-based bispecific T-cell engager (TCER), in recurrent or refractory solid tumors
Presenting author: Martin Wermke, MD
Session: Developmental Therapeutics – Immunotherapy
Abstract ID: 2507
Abstract/Slides Link: Developmental Therapeutics—Immunotherapy

For more information about the presentation, read the full press release here and for details about the conference here.